Every SEC filing alert our engine sent, newest first: 8-K material events, deals, capital raises, leadership changes, results and insider buying and selling.
Phoenix Education Partners reported fiscal year 2026 net revenue of $1,017.0 million and net income of $88.9 million. The company also announced the appointment of Michael Weston, a Principal at Apollo Global Management, to its Board of Directors as a Class II director.
Term
FY2026
“As workforce needs evolve, the value of higher education increasingly lies in the knowledge and skills students develop and can apply in a changing workplace. We’re focused on providing that value through programs that deliver career-relevant skills, expanding offerings aligned with in-demand fields, and strengthening our relationships with employers to better understand and meet their workforce needs. With strong student retention and continued investment in the student experience, we remain focused on providing working adults with a relevant, high-quality education that meets their evolving needs.”
Chris Lynne, Chief Executive Officer of Phoenix Education Partners and President of the University of Phoenix
Alamar Biosciences reported Q3 2026 revenue of $33.5 million, a 68% year-over-year increase driven by strong demand for its NULISA platform and consumables. The company raised its full-year 2026 revenue guidance to a range of $121-$123 million and announced the retirement of President Tod White effective December 31, 2026.
Term
Q3 2026
“Our third quarter results reflect continued strong demand for our platform, with revenue up 68% and biopharma customers accounting for the largest portion of our revenue for the first time. Our selection by UK Biobank and new collaboration with GSK show that leading institutions and drug developers are choosing NULISA to reach the low-abundance proteome at scale.”
Yuling Luo, PhD, founder, CEO, and chair of Alamar Biosciences
“Tod has been an outstanding partner and leader during a pivotal period for Alamar. He helped build the foundation that is driving our growth today, managed multiple rounds of fundraising, and leaves the company well-positioned for its next phase. On behalf of our board and the entire team, I thank Tod for his many contributions and wish him the very best in his retirement.”
Yuling Luo, Ph.D., Founder, Chief Executive Officer, and Chair of the Company
Joby Aviation Insider Paul Cahill Sciarra Sells $311K of Stock
Paul Cahill Sciarra sold 62,500 shares of Joby Aviation, Inc. at $4.97 a share, worth $311K in total on Nov 2, 2026. Shares held after the trade: 55,578,057 (-0.1%).
Automatic Data Processing Corporate VP Michael A. Bonarti Sells $2.25M of Stock
Michael A. Bonarti, Corporate VP, sold 7,487 shares of Automatic Data Processing Inc at $300.00 a share, worth $2.25M in total on Nov 2, 2026. Shares held after the trade: 81,849 (-8.4%).
Marqeta reported Q3 2026 financial results with Total Processing Volume (TPV) growing 29% year-over-year to $126 billion. The company achieved its third consecutive quarter of GAAP profitability with net income of $115 million, aided by a $107 million non-cash income tax benefit.
Term
Q3 2026
“Our third quarter results demonstrate the durable, differentiated business Marqeta is building, as well as our focus on enhancing the platform that customers trust to build and scale their payment programs. TPV surpassed a $500 billion annualized run rate for the first time, Adjusted EBITDA margin set a new high-water mark, and we delivered our third consecutive quarter of GAAP profitability.”
Astera Labs reported record third-quarter 2026 revenue of $584.9 million, representing 154% year-over-year growth driven by high-volume production of its Scorpio fabric switches. The company achieved a GAAP net income of $182.9 million ($0.99 per diluted share) and expanded its product portfolio with the introduction of the Aries 7 PCIe 7 signal conditioning line and the Orion rack-scale reference architecture.
Term
Q3 2026
“Astera Labs delivered outstanding Q3 2026 results, with record quarterly revenue of $584.9 million, up 49% sequentially and up 154% year-over-year, with broad-based growth led by Scorpio, which ramped to high-volume production and became our largest product family by revenue.”
Automatic Data Processing Insider Carlos A. Rodriguez Sells $3.39M of Stock
Carlos A. Rodriguez sold 11,305 shares of Automatic Data Processing Inc at $300.02 to $300.06 a share (average $300.05) in 5 transactions, worth $3.39M in total on Nov 2, 2026. Shares held after the trade: 22,873 (-13.1%).
QuidelOrtho reported Q3 2026 revenue of $619 million, a 12% decrease year-over-year primarily due to lower sales in China and a softer respiratory season. The company also announced a major cost transformation and restructuring program expected to deliver over $80 million in annual savings by 2027, involving a shift to two focused business units: Core Diagnostics and Point of Care Diagnostics.
Term
Q3 2026
“The underlying performance of our Labs and Immunohematology businesses remained solid in the third quarter, supported by the strength and durability of our customer relationships and our large global installed base. While China and a softer respiratory season continue to pressure our results, we are taking decisive action to strengthen the Company through a new cost transformation and enterprise restructuring program.”
Brian J. Blaser, President and Chief Executive Officer
BlueLinx reported fiscal third quarter 2026 net sales of $813 million, an 8.5% increase year-over-year, driven by growth in both specialty and structural products. Despite the sales growth, the company recorded a net loss of $0.6 million due to an unusual inventory provision related to a strategic brand change, though Adjusted EBITDA rose 42% to $31.7 million.
Term
3 months
“Our strategy and our investments in growth initiatives, operational excellence, and process improvements are helping us successfully navigate a challenging environment and drive long-term value creation.”
Shyam Reddy, President and Chief Executive Officer
“Strong operational execution and effective working capital management contributed to our strong cash flow during the third quarter. Our balance sheet and liquidity remain strong, which give us a great deal of flexibility to execute on our strategic initiatives.”
Kelly Wall, Senior Vice President, Chief Financial Officer and Treasurer
Enhanced Group Inc. has filed a Certificate of Amendment to its Charter to effect a 1-for-10 reverse stock split of its Class A and Class B common stock. Additionally, the company entered into amendments to Transaction Support Agreements with its CEO and controlling shareholders to extend lock-up restrictions, eliminating a scheduled six-month partial release in favor of a full twelve-month lock-up period.
Nisource EVP & CFO Shawn Anderson Sells $292K of Stock
Shawn Anderson, EVP & CFO, sold 6,500 shares of Nisource Inc. at $45.00 a share, worth $292K in total on Oct 30, 2026. Shares held after the trade: 160,080 (-3.9%).
Corcept Therapeutics reported Q3 2026 revenue of $340.5 million, a 64% increase year-over-year, driven by strong growth in Korlym and the rapid uptake of Lifyorli in ovarian cancer. Net income rose significantly to $126.8 million, or $1.01 per diluted share, while the company reiterated its full-year 2026 revenue guidance of $1.1 billion to $1.2 billion.
Term
Q3 2026
“Awareness of the importance of diagnosing and treating patients with Cushing’s syndrome is steadily increasing and is driving the growth of our endocrinology business. Lifyorli’s uptake in ovarian cancer has been both very rapid and broad. Since its April 1st launch, more than 2,300 patients have received the medication. More than 1,700 physicians have prescribed it. We expect continued growth in both businesses and have reiterated our 2026 revenue guidance of $1.1 – $1.2 billion.”
Joseph K. Belanoff, MD, Corcept’s Chief Executive Officer
“The ADA and EASD consensus statement is an important advance for the many patients whose difficult-to-control hyperglycemia is a manifestation of undiagnosed Cushing’s syndrome. Optimal care starts with screening and a correct diagnosis. The ADA/EASD report also identifies mifepristone as a potential treatment, citing the positive results of our CATALYST trial.”
Bill Guyer, PharmD, Corcept’s Chief Development Officer
For the nine months ended September 30, 2026, AES Corp reported total assets of $56.05 billion and a significant increase in retained earnings to $1.85 billion compared to $641 million at year-end 2025. The company maintained a strong liquidity position with $1.97 billion in cash and cash equivalents while managing a total debt load of approximately $33.26 billion.
American Express Group Pres., GMNS Anna Marrs Sells $14.7M of Stock
Anna Marrs, Group Pres., GMNS, sold 44,910 shares of American Express Co at $326.63 to $327.77 a share (average $327.20) in 3 transactions, worth $14.7M in total on Nov 2, 2026. Shares held after the trade: 20,509 (-39.6%).
HNI Corporation reported net sales of $1,592.9 million for the third quarter of 2026, a significant increase from $683.8 million in the prior year period. Despite the revenue growth, nine-month net income attributable to the corporation slightly decreased to $102.3 million compared to $103.4 million in 2025, impacted by higher interest expenses and restructuring costs.
Tarsus Pharmaceuticals reported a significant net loss of $693.9 million for the nine months ended September 30, 2026, primarily driven by $632.2 million in acquired in-process research and development expenses from the acquisitions of iRenix and Alkeus. Despite the net loss, total revenues grew to $530.5 million, up from $299.7 million in the prior year, fueled by strong product sales.
Mercury General Corp reported a net loss of $13.7 million for the third quarter of 2026, primarily driven by $261.9 million in net realized investment losses. Despite the quarterly loss, the company maintained a net income of $440.2 million for the first nine months of 2026, supported by a 10.7% year-over-year increase in net premiums earned.
Contineum Therapeutics reported third-quarter 2026 financial results, highlighting a net loss of $18.7 million and a cash position of $244.5 million. The company noted that its current capital resources are sufficient to fund operations through mid-2029, providing runway past the estimated completion of its Phase 2 PROPEL-IPF clinical trial. Research and development expenses increased 45% year-over-year to $16.0 million, primarily driven by the PIPE-791 program.
“Lysophosphatidic acid 1 receptor (LPAR1) antagonism as a treatment approach for pulmonary fibrosis has exceptionally strong clinical validation with multiple trials successfully completed including more than 1,600 patients. We believe the LPAR1 class can be the ideal backbone for combination treatments. Our LPAR1 antagonist, PIPE-791, is potentially differentiated in key ways including a favorable safety and tolerability profile, sustained target engagement which we believe has the potential for improved efficacy, and superior convenience in a one-time daily, low oral dose with no titration required for patients.”
Carmine Stengone, CEO, Contineum Therapeutics
“We continue to expand our footprint for PROPEL-IPF, with over 100 sites now online in 16 countries to facilitate a steady pace of enrollment. With a projected cash runway that extends through mid-2029, we are well positioned with capital resources one year past the estimated completion of our idiopathic pulmonary fibrosis (IPF) trial.”
LENZ Therapeutics transitioned to a commercial-stage company following the FDA approval of VIZZ in July 2025, reporting its first product sales of $6.0 million for the nine months ended September 30, 2026. Despite the new revenue stream, the company saw a significant increase in net loss to $104.4 million for the same period, driven primarily by a surge in selling, general, and administrative expenses to $120.2 million.
Rhythm Pharmaceuticals reported total revenues of $223.5 million for the nine months ended September 30, 2026, a significant increase from $132.5 million in the prior year period. Despite the revenue growth, the company recorded a net loss of $146.3 million due to increased selling, general, and administrative expenses and research and development costs.
Atlantic Union Bankshares Corp reported net interest income of $965.9 million for the nine months ended September 30, 2026, compared to $824.7 million in the prior year. The company completed the acquisition of Sandy Spring Bancorp on April 1, 2025, and authorized a $250 million share repurchase program in May 2026.
Zevra Therapeutics reported Q3 2026 net revenue of $37.8 million, a 45% increase year-over-year, primarily driven by $34.0 million in sales from MIPLYFFA. The company achieved net income of $19.2 million for the quarter and maintained a strong cash position of $270.9 million to support its rare disease pipeline.
Term
Q3 2026
“In the third quarter, we made continued progress across our business, building on MIPLYFFA's commercial performance in the U.S. and advancing our pipeline in support of our mission to redefine what’s possible in bringing life-changing therapies to people living with rare disease.”
Neil F. McFarlane, Zevra's President and Chief Executive Officer
“We remain focused on reaching more people living with Niemann-Pick disease type C, advancing celiprolol for vascular Ehlers-Danlos syndrome, and pursuing European access to arimoclomol. Our strong financial position enables us to advance these priorities while continuing to make arimoclomol available to eligible patients through our global Expanded Access Program.”
Neil F. McFarlane, Zevra's President and Chief Executive Officer
Navitas Semiconductor reported Q3 2026 revenue of $14 million, representing 33% sequential and 38% year-over-year growth. The company is undergoing a strategic shift toward high-power markets like AI Data Centers, which are expected to account for over 40% of total revenue by year-end as it exits the mobile and low-end consumer segments.
Term
Q3 2026
“Our strong third quarter results and the continued acceleration in high-power markets reflect the successful execution of our Navitas 2.0 transformation. By year-end, we expect mobile and low-end consumer revenue to be essentially eliminated from our mix, further positioning the Company as a high-power business with AI Infrastructure, composed of AI Data Centers and energy grid infrastructures that power them, expected to account for more than 40% of total revenue.”
Chris Allexandre, President and CEO
“Our third quarter results demonstrate the sustained momentum from our Navitas 2.0 transformation, with revenue of $14 million representing 33% sequential growth and 38% year-over-year growth—the first quarter of year-over-year growth since 2024.”
Ouster reported record third-quarter 2026 revenue of $59 million, a 50% year-over-year increase, driven by strong demand in industrial and robotics verticals. The company shipped over 27,000 units, including record shipments of Stereolabs cameras and the initial ramp of its new Rev8 native color lidar. Net loss improved to $14 million as the company moves toward its goal of profitability.
“We delivered a strong third quarter, with $59 million in revenue and more than 27,000 total sensors shipped, cementing Ouster’s evolution into a comprehensive platform that meets the diverse, global demands of Physical AI.”
Angus Pacala, Ouster CEO
“The market reception for Rev8 has been decisive. As the world’s first native color lidar, Rev8 is a paradigm shift that is proving to be an undeniable competitive differentiator. Hundreds of customers have already chosen Rev8 for their mission critical applications.”
Coupang reported Q3 2026 financial results with net revenues of $10.0 billion, a 7% increase year-over-year. The company swung to a net loss of $501 million, significantly impacted by costs related to a fulfillment center fire in Korea. During the quarter, Coupang also repurchased 12.7 million shares of Class A common stock for $201 million.
Sprout Social reported Q3 2026 revenue of $125.1 million, an 8% increase year-over-year, and achieved a record non-GAAP operating income of $26.3 million. The company highlighted strong growth in its enterprise customer cohorts and initiated a $50 million stock buyback program, repurchasing over $26 million in shares during the quarter.
Term
Q3 2026
“We are pleased with our financial performance this quarter, highlighted by a record non-GAAP operating income of $26.3 million, equating to a 21% non-GAAP operating margin. We posted an 18% year-over-year increase in approximated trailing twelve month subscription revenue contribution from our $30k+ ARR customer cohort and our Non-GAAP free cash flow was $26.7 million, an increase of 158% year-over-year.”
Ryan Barretto, CEO of Sprout Social
“We also initiated our $50 million stock buyback program with over $26 million of repurchases in Q3, which allows us to return value to shareholders and offset dilution. Importantly, we are targeting GAAP profitability looking ahead, a significant milestone that reflects our focus on cost discipline.”
Ultragenyx reported Q3 2026 total revenue of $173 million and a net loss of $118 million, while announcing a major restructuring plan to reduce its workforce by 20%. The company also confirmed the sale of two Priority Review Vouchers for $413 million and reaffirmed its 2026 revenue guidance and 2027 profitability targets.
Term
Q3 2026
“We received two BLA approvals from the FDA within one month for our first gene therapy treatments and the launches are progressing well with growing demand for these products. With substantial reductions in headcount and expenses, combined with two launches and continued growth in our base business, we expect meaningful profitability in 2027 and going forward.”
Emil D. Kakkis, M.D., Ph.D., chief executive officer and president of Ultragenyx
Cricut, Inc. reported Q3 2026 revenue of $188.6 million, an 11% increase year-over-year, driven by strong growth in its Products segment and international markets. The company also announced a recurring semi-annual dividend of $0.10 per share and a special dividend of $0.70 per share, alongside a replenishment of its $50 million stock repurchase program.
Term
Q3 2026
“We delivered a strong third quarter, with revenue up 11% year-over-year, driven by 17% growth in Products and continued growth in Platform revenue. Double-digit sell-out growth for the second consecutive quarter, rising active users, and more than 3.07 million paid subscribers reflect the progress we are making to broaden our reach and deepen engagement.”
Ashish Arora, Chief Executive Officer of Cricut
“We generated $23.7 million in cash from operations during the quarter and ended Q3 with $273 million in cash and cash equivalents. Our profitable business model, strong balance sheet, and cash generation give us the flexibility to continue investing in innovation, international expansion, and marketing, while also returning capital to shareholders.”
InnovAge Holding Corp. reported financial results for its fiscal first quarter ended September 30, 2026, with revenue increasing 12.1% year-over-year to $264.8 million. Net income rose significantly to $20.9 million, or $0.14 per share, driven by census growth and disciplined clinical execution. The company ended the quarter with approximately 8,420 participants and $163 million in total cash and short-term investments.
Term
Q1 2027
“We are pleased with our strong stat to fiscal 2027, as continued census growth along with disciplined clinical and operational execution drove strong financial performance. Our first quarter results reinforce the progress we have made over the past serval years and our confidence in the long-term potential of the business.”
Patrick Blair, Chief Executive Officer of InnovAge
DiamondRock Hospitality reported strong Q3 2026 results with net income of $33.3 million and a 6.6% increase in Comparable RevPAR. The company raised its full-year 2026 guidance and increased its quarterly dividend by 22% to $0.11 per share following robust demand in transient and group segments.
Term
Q3 2026
“We delivered another strong quarter, exceeding our expectations with healthy demand and higher rates across both transient and group segments. Combined with the operating efficiencies we have built across the portfolio, that drove outsized Hotel Adjusted EBITDA growth and, importantly, higher free cash flow. Given the strength of our third quarter results and our fourth quarter booking pace, we are raising our 2026 guidance again.”
Jeffrey J. Donnelly, Chief Executive Officer of DiamondRock Hospitality Company
“Looking ahead to 2027, we see a constructive industry backdrop and strong earnings drivers across our portfolio. We expect to grow earnings through continued operating execution and the ramp of our recently renovated hotels, while our free cash flow and balance sheet provide significant flexibility to deploy capital at attractive returns. That is our flywheel: grow earnings, generate more free cash flow and reinvest that capital at attractive returns to drive further growth.”
Jeffrey J. Donnelly, Chief Executive Officer of DiamondRock Hospitality Company